News & Media

Ronny Drapkin, MD, PhD, discusses risk factors for ovarian cancer, the importance of raising awareness among PCPs and OB-GYNs, and when health care providers should discuss family history and genetic testing with their patients.

Ronny Drapkin, MD, PhD, Basser's director of Gynecologic Cancer Research, discussed why it’s difficult to detect ovarian cancer in its earliest stages and how new drugs like PARP inhibitors have made a difference in ovarian cancer treatment.

A recent study from Kara Maxwell, MD, PhD showed only a small percentage of men recommended to undergo genetic testing due to personal or family history of cancer actually received it.

Dr. Kara Maxwell and Dr. Jennifer Zhang talk about breast cancer screening and genetic testing in men and what to know about risk, screening and treatment - including surgery and ongoing treatment/hormone therapy options.

Susan Domchek, MD, Basser executive director, discussed her path to breast cancer genetics research and how the Basser Center is working to improve care and future outcomes for people with a family history of cancer, including BRCA mutation carriers.

Filko Prugo, a BRCA2 mutation carrier who is participating in the Basser Center's cancer prevention vaccine trial, shares why clinical trial participation is vital to progress research.

Kara Maxwell, MD, PhD, director of the Men & BRCA program, discussed team research on optimizing genetic testing to better inform decision-making in prostate cancer treatment and germline mutations in racially diverse cohorts of patients.

Kara Maxwell, MD, PhD, discusses research on genetic testing results in metastatic prostate cancer patients and results of prostate cancer genetic testing in diverse populations.

Kara Maxwell, MD, PhD, Men & BRCA program director, called out the potential for spatial technologies to make an impact in the early cancer prevention or intervention setting in an interview with OncLive on the 2024 Annual AACR Meeting.

Susan M. Domchek, MD, Basser Center executive director, and Robert H. Vonderheide, MD, DPhil, director of the ACC, report on cancer interception development with rapid advances in technology, therapeutics, and genetic testing methods.